BridgeMD
New treatment option for Cannabis Use
Official title Extended Effects of Cannabis Abstinence on Clinical Symptoms and Cognition in Depression
ClinicalTrials.gov ID: NCT04935619
What this study is testing
- What it's testing
- The prevalence of major depressive disorder (MDD) is \~5.0%, and rates of co-occurring SUDs in these patients approach 40-50%. Specifically, rates of co-morbid cannabis use disorder (CUD) in patients with MDD are elevated 2-3 fold compared to 2.9% in the general population, and is associated with poorer treatment outcomes and impaired cognitive and psychosocial functioning in comparison to MDD patients without CUD.
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 55
You may be able to join if
- All participants must be between the ages 18-55
- Meet SCID for DSM-5 diagnostic criteria for cannabis use disorder, moderate to severe
- Meet SCID for DSM-5 diagnostic criteria for Major Depressive Disorder
- Be an outpatient receiving a stable dose of antidepressant medication for at least three months (to ensure stability of depressive symptoms
- Have a Hamilton Depression Rating Scale (HDRS-17) at baseline assessment in the range of 12-25..
You likely can't join if
- Meets criteria for substance use disorder of alcohol or other illicit substances within the past 6 months (with the exception of cannabis, nicotine...
- Positive urine screen for illicit substances other than cannabis, nicotine, or caffeine
- Current suicidal or homicidal ideation
- Psychotic disorder diagnosis (e.g. schizoaffective disorder, major depression with psychotic features) as determined by the SCID
- Treatment seeking for cannabis use
- Meet SCID for DSM-5 diagnostic criteria for Bipolar Disorder
See the full eligibility criteria
- All participants must be between the ages 18-55
- Meet SCID for DSM-5 diagnostic criteria for cannabis use disorder, moderate to severe
- Meet SCID for DSM-5 diagnostic criteria for Major Depressive Disorder
- Be an outpatient receiving a stable dose of antidepressant medication for at least three months (to ensure stability of depressive symptoms
- Have a Hamilton Depression Rating Scale (HDRS-17) at baseline assessment in the range of 12-25..
- Have a Full-Scale IQ ≥ 80 as determined by the WTAR
- Be a non-treatment seeking cannabis user
- Evidence of sufficient motivation and effort as measured by a Test of Memory Malingering (TOMM) score ≥ 45.
- Meets criteria for substance use disorder of alcohol or other illicit substances within the past 6 months (with the exception of cannabis, nicotine, or caffeine)
- Positive urine screen for illicit substances other than cannabis, nicotine, or caffeine
- Current suicidal or homicidal ideation
- Psychotic disorder diagnosis (e.g. schizoaffective disorder, major depression with psychotic features) as determined by the SCID
- Treatment seeking for cannabis use
- Meet SCID for DSM-5 diagnostic criteria for Bipolar Disorder
- Head Injury\> 5 minutes LOC
- Exceed upper and lower cut-offs on HSRD-17 (See Inclusion Criteria)
The study team makes the final eligibility decision.
Where it's taking place
- Toronto, Ontario, Canada
Compensation & support
A stipend or compensation may be offered.
Compensation likely.
ClinicalTrials.gov doesn't provide a reliable structured field for payment or travel support - confirm details with the study team.
Questions & answers
Do participants get paid in this trial?
This study's listing includes signals that participants may be compensated or receive a stipend. Amounts vary and are set by the study team - confirm the details with them.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 55 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Toronto, Ontario, Canada. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.